The Heart Protection Study: High-risk patients benefit from statins, regardless of LDL-C level
Hitinder S. Gurm, MBBS
Department of Cardiovascular Medicine, The Cleveland Clinic
Byron Hoogwerf, MD
Department of Endocrinology and Metabolism; Section of Preventive Cardiology, Department of Cardiovascular Medicine, Director; Internal Medicine Residency Program, The Cleveland Clinic
Address: Hitinder S. Gurm, MBBS, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Hoogwerf has indicated that he is a consultant for Astra Zeneca and Merck, and is on the speakers’ bureau for Merck and Schering Plough.
ABSTRACTThe landmark Heart Protection Study (Lancet 2002; 360:7-22) found benefit in treating subjects at high risk of a coronary event with simvastatin 40 mg daily, regardless of baseline low-density lipoprotein cholesterol level and in all subgroups, including women and the elderly. The study found no benefit of simvastatin therapy in preventing noncardiac events (eg, dementia, osteoporotic fractures), and no negative effects, such as an increase in cancer, respiratory disease, or suicide.